We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking the Acsl14 Enzyme Prevents Ferroptosis-Linked Cell Death

By Gerald M. Slutzky, PhD
Posted on 25 Nov 2016
Inhibiting the enzyme Acsl4 (acyl-CoA synthetase long-chain family member 4), which is involved in fatty acid metabolism, has been postulated to be a viable therapeutic approach to preventing ferroptosis-related diseases.

Ferroptosis, a poorly understood form of programmed cell death, has been implicated in the pathological cell death found in neuronal and kidney tissues. More...
It may also be possible to selectively trigger ferroptosis in certain cancer cells. Previously, only a few essential molecules, such as glutathione peroxidase 4 (Gpx4), have been implicated in the ferroptotic process.

Investigators at Helmholtz Zentrum München (Germany) applied two independent approaches - a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines - to generate new details as to how ferroptosis works.

They reported in the November 14, 2016, online edition of the journal Nature Chemical Biology that ACSL4 was as an essential component for ferroptosis execution. Specifically, cells in which the genes for both Gpx4 and Acsl4 proteins had been removed showed marked resistance to ferroptosis. Mechanistically, Acsl4 enriched cellular membranes with long polyunsaturated omega-6 fatty acids. Targeting Acsl4 with thiazolidinediones, a class of antidiabetic compound, prevented tissue destruction in a mouse model of ferroptosis, Moreover, Acsl4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis.

"The individual mechanisms involved in this type of cell death remain only partly understood, and our findings make an important contribution towards a better understanding of ferroptotic cell death," said senior author Dr. Marcus Conrad, head of a research group at the institute of developmental genetics at the Helmholtz Zentrum München. "Our intriguing insights that the Acsl4 enzyme plays a substantial role in the process of cell death provide novel cues for yet-unrecognized therapeutic approaches towards inhibiting ferroptosis in degenerative diseases or inducing ferroptosis in certain tumor diseases. In particular, tumors that are otherwise very difficult to treat with standard chemotherapy might be amenable for ferroptosis therapy."

Related Links:
Helmholtz Zentrum München


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.